UNDERSTANDING ACMG GUIDELINES & CLINICAL CLASSIFICATION OF GENETIC VARIANTS

“𝓝𝓸 𝓼𝓲𝓷𝓰𝓵𝓮 𝓵𝓪𝓫𝓸𝓻𝓪𝓽𝓸𝓻𝔂 𝓱𝓪𝓼 𝓮𝓷𝓸𝓾𝓰𝓱 𝓭𝓪𝓽𝓪; 𝓬𝓸𝓵𝓵𝓪𝓫𝓸𝓻𝓪𝓽𝓲𝓿𝓮 𝓬𝓾𝓻𝓪𝓽𝓲𝓸𝓷 𝓲𝓼 𝓽𝓱𝓮 𝓯𝓾𝓽𝓾𝓻𝓮 𝓸𝓯 𝓰𝓮𝓷𝓸𝓶𝓲𝓬 𝓶𝓮𝓭𝓲𝓬𝓲𝓷𝓮.” - Professor Heidi Rehm

🧬 Genomic medicine has moved from discovery to daily clinical decision-making. At the center of this shift are the 2015 standards from the American College of Medical Genetics & Genomics (ACMG), which established a structured framework for interpreting sequence variants.

   🔹 Genetic variants influence disease risk, diagnosis, prognosis, & therapeutic strategy. Without standardized interpretation, clinical decisions become inconsistent. The ACMG/AMP framework addresses this by integrating multiple evidence streams into five categories:

1. Pathogenic (Class 5)

2. Likely Pathogenic (Class 4)

3. Variant of Uncertain Significance [VUS] (Class 3)

4. Likely Benign (Class 2)

5. Benign (Class 1)

This tiered system reduces interpretive subjectivity & improves reproducibility across laboratories.

   🔹 The ACMG model is not opinion-based; it is evidence-calibrated.

 Key evidence domains include:

• Population Data

• High allele frequency in reference datasets (e.g., gnomAD)

• Functional Evidence 

• Well-validated in vitro or in vivo assays

• Segregation & Inheritance

• Co-segregation in affected families, de novo occurrence, or consistency with known inheritance patterns,

• Computational & Predictive Tools

• In silico predictions (splicing, conservation, structural modeling)

• Published & Curated Clinical Data

• Peer-reviewed case reports, case-control studies, & expert panel curation.

This multi-layered synthesis reflects a Bayesian logic even when not formally described as such.

   🔹 Accurate classification directly shapes:

• Diagnostic precision (reducing misdiagnosis & unnecessary interventions).

• Therapeutic targeting

• Risk stratification & prevention

• Genetic counseling (guiding cascade testing & reproductive planning).

Importantly, the most challenging category remains the VUS, which underscores the need for data sharing & functional validation.

     ➡️ Despite standardization, variability persists due to:

• Underrepresentation of non-European populations in genomic databases,

• Limited functional assays for rare variants,

• Incomplete penetrance & variable expressivity, &

• Discordance between laboratories

The future lies in collaborative curation (e.g., ClinGen), population-diverse datasets, machine learning refinement, & real-world clinical outcome integration.

⚠️ In an Oystershell, for genomic medicine to be highly sophisticated, variant classification must transition from static interpretation to dynamic, continuously updated models, powered by global data sharing & interdisciplinary collaboration.

Abubakar Abubakar ✍🏻

• Richards S, et al. 2015;17(5):405-424.

• Rehm HL, et al. N Engl J Med. 2015;372:2235-2242.

#ACMG #ClinGen #PGT⚕️